ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NVO vs PFE // 10Y YIELD & FRED MACRO BETA

Novo Nordisk A/S (NYSE) VS. Pfizer Inc. (NYSE) • 15-METRIC TALLY: NVO 4 — PFE 7
▲ 10Y YIELD & FRED MACRO BETA LEADER: PFE
macro-sensitivity
0.87
macro-sensitivity
1.05
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NVO VS. PFE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NVO PFE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 74.30% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 9.90% 5.10% +4.80 NVO /roic <GO>
EV/EBITDA & P/E Valuation 21.0x 19.7x +1.30 PFE /valuation <GO>
Free Cash Flow Yield 2.21% 5.32% -3.11 PFE /fcf-yield <GO>
Operating Margin 13.90% 15.10% -1.20 PFE /operating-margins <GO>
Net Profit Margin 10.90% 12.40% -1.50 PFE /net-margins <GO>
Revenue Growth (YoY) 2.20% -1.60% +3.80 NVO /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.74 2.10 +1.64 NVO /balance-sheet <GO>
Piotroski F-Score Quality 7/9 7/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 47.9 58.5 -10.60 PFE /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE 0.87 1.05 -0.18 PFE /macro-sensitivity <GO>
Forward P/E Multiple 30.5x 20.5x +10.00 PFE /forward-pe <GO>
Enterprise Scale & Market Cap $173.31B $170.71B $2.60B NVO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NVO REV PFE REV NVO GROSS % PFE GROSS % NVO FCF PFE FCF
FY 2025 — $62.58B — 74.3% — $9.07B
FY 2024 — $63.63B — 71.9% — $9.84B
FY 2023 — $50.91B — — — $6.41B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NVO // BETA 0.87
PFE // BETA 1.05